Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
The annual meeting will be held virtually on June 18, 2026, with shareholders voting on key proposals including director election, a reverse stock split, auditor ratification, and executive compensation approval.
Shareholders of record as of April 24, 2026, are entitled to vote, with 36,438,703 shares outstanding.
Voting can be conducted online, by phone, mail, or during the virtual meeting, with detailed instructions provided.
The board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of one Class I director (Seth J. Herbst, M.D.) for a term expiring in 2029.
Proposal 2: Authorization for a reverse stock split at a ratio between 2:1 and 10:1, at the board's discretion, to address Nasdaq listing compliance.
Proposal 3: Ratification of Crowe LLP as independent auditor for 2026.
Proposal 4: Advisory vote on 2025 executive compensation.
Shareholder proposals for the 2027 meeting must be submitted by January 11, 2027.
Board of directors and corporate governance
The board consists of four members, with a classified structure and separation of CEO and Chairman roles.
All directors attended 2025 board and committee meetings; independence is determined per Nasdaq standards.
Committees include Audit, Compensation, and Nominating, each with defined charters and independent members.
The board actively oversees risk, including financial, compliance, and IT risks.
Shareholder communications are facilitated through direct correspondence with the board.
Latest events from Dyadic International
- Commercial stage reached with six product launches, global distribution, and early recurring revenues.DYAI
Lytham Partners Spring 2026 Investor Conference28 May 2026 - Commercializing animal-free proteins with scalable platforms and recurring revenues across key markets.DYAI
Sidoti Micro-Cap Virtual Conference20 May 2026 - Commercial-stage protein innovator drives growth with animal-free products and global partnerships.DYAI
Investor presentation20 May 2026 - Q1 2026 revenue rose 182% to $1.11M, with net loss narrowing and global expansion underway.DYAI
Q1 202619 May 2026 - Shareholders will vote on director election, reverse stock split, auditor ratification, and executive pay.DYAI
Proxy filing12 May 2026 - C1 platform delivers rapid, high-yield, animal-free biologics with proven safety and global validation.DYAI
Investor presentation1 May 2026 - Net loss widened to $7.36M on lower revenue, with expanded commercialization and partnerships.DYAI
Q4 202525 Mar 2026 - Commercial product launches and partnerships are driving revenue growth, with more expected by 2027.DYAI
Life Sciences Virtual Investor Forum12 Mar 2026 - Rapid commercialization in non-therapeutic markets targets profitability by 2026.DYAI
Small-Cap Virtual Conference3 Feb 2026